GANX
Gain TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
GT-02287 has generated biomarker and target-engagement signals, management is guiding to IND clearance in 2Q26 and Phase 2 start in 3Q26, and successful execution could re-rate shares from a depressed base [#8-K-2026-03-26].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Going-concern disclosure and likely need for additional capital.
Momentum
82
Value
41
Sentiment
53
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.80 · Bull $3.40 · Bear $0.80
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $7.60
Why
Momentum82 · Δ7d -
Value41 · Δ7d +0.1
Sentiment53 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
82
34% active weight
Current posture
7d trendFlat
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
53
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 82.4 / Value 41.1 / Sentiment 52.7
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$83.6M
Beta
0.07
Shares Out
38.46M
P/E (TTM) · Derived
-2.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.82
Rev YoY
-
EPS YoY
+10.7%
Gross Margin
-
Op Margin
-
Net Debt
-$9.95M
Current Ratio
2.52
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology